Site Editors
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Posted: Tuesday, March 19, 2024
In the real world, patients with multiple myeloma who are prescribed the anti-CD38 monoclonal antibody daratumumab experience high-dosing adherence as well as dosing frequency similar to those on the approved label, according to results of a retrospective study published in Mayo Clinic Proceedings. The duration of daratumumab use was found to be longer than previously observed in this patient population, noted Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, and colleagues.
The team’s conclusions were based on de-identified data from 2,124 U.S. patients with multiple myeloma, none of whom had received a stem cell transplant, who were treated with a daratumumab-containing regimen between November 2015 and March 2021. This was the first examination of the continuous duration of daratumumab treatment and dosing frequency across multiple lines of therapy, emphasized the authors.
Across all patients in the study, those initiating daratumumab remained on therapy for a median of 16.6 months. Also, 63.5%, 33.1%, and 14.5% continued daratumumab at 12, 24, and 36 months, respectively. These figures were even higher for a subgroup (n = 1,246) of patients with 12 months or more of continuous insurance coverage: For them, the median length of daratumumab use was 24.7 months, and 99.4%, 51.8%, and 22.8% remained on daratumumab treatment at 12, 24, and 36 months, respectively.
“The real-world dose adherence ratios—observed daratumumab doses relative to the label—were close to 1.0, particularly among patients with longer follow-up,” noted Dr. Fonseca and co-investigators. “Adherence with the approved prescribing information [was] high, particularly among patients with longer daratumumab use.”
Disclosure: The study authors’ disclosure information can be found at mcpiqojournal.org.
